In the first case, mutations occur in the extracellular SEMA domain, likely affecting the ligand–receptor interaction or the ability of MET to dimerize, and have been detected in lung, gastric, and breast cancer [48], as well as in cancers of unknown primary (CUPs) [52]. This evidence concerns the gene MET and breast carcinoma.